Current reports
Current report No. 18/2022 – List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022
Current report No. 18/2022 Date prepared: June 23, 2022 Abbreviated name of the issuer: CELON PHARMA S.A. Subject: List of shareholders holding at least 5% of the votes at the Ordinary General Meeting of the Company held on June 22, 2022 Legal basis subs. 70 point 3 of the Act on Public Offering – GeneralRead more »
Current report No. 17/2022 – Resolutions adopted by the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022
Date prepared: June 22, 2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) hereby publishes the text of the resolutions adopted by the Ordinary General Meeting of the Company on JuneRead more »
Current report No. 16/2022 – Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021
Current report No. 16/2022Date prepared: June 22, 2022Abbreviated name of the issuer: CELON PHARMA S.A.Subject: Resolution of the Ordinary General Meeting of the Company on coverage of loss and payment of the dividend for the financial year 2021Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodicalRead more »
Current report No. 15/2022 – Information on the status of the application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy
Date: June 20, 2022, 7:42 AMLegal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. In relation to the current report No. 10/2022 of April 20, 2022 on the submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamineRead more »
Current report No. 14/2022 – Supplementing the documentation for the Ordinary General Meeting of Celon Pharma S.A. convened to take place on June 22, 2022
Date prepared: June 15, 2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: As a supplement to current report No. 13/2022 dated May 26, 2022 announcing the Ordinary General Meeting of Celon Pharma S.A. convened to take place on JuneRead more »
Current report No. 13/2022 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022 with draft resolutions
Subject: Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 22, 2022 with draft resolutions Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (“the Company”), acting pursuantRead more »
Current report No. 12/2022 – The Management Board’s and the Supervisory Board’s recommendation on the coverage of loss for the year 2021 and payment of the dividend
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: May 25, 2021, 5:26 PM Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) informs that on May 25, 2022 it adopted a resolution on recommendation for the Ordinary General Meeting of the Company onRead more »
Current report No. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
Current report No. 11/2022Date prepared: 2022-23-05, at 4:14 pmAbbreviated name of the issuer: CELON PHARMA S.A. In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management Board of the Company informs that today it has receivedRead more »
Current report No. 10/2022 – Submission of an application to the Food and Drug Administration (FDA) for the granting the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 20, 2022 an application was submitted to the Food and Drug Administration (FDA) for the granting of the Breakthrough Designation to Falkieri (Celon’s esketamine DPI) in treatment-resistant bipolar depression therapy. This application is supported by results of pre-clinical and clinical trials,Read more »